About & Ownership Disclosure
A plain-English summary of who runs this site, why it exists, how rankings are produced, and what readers should weigh when interpreting our editorial coverage of GLP-1 telehealth providers.
Affiliate & ownership disclosure (top of page): TirzepatideReview.com is operated by people affiliated with NexLife Inc., a U.S. telehealth MSO that offers compounded GLP-1 weight management programs. We are not a fully independent third party with respect to NexLife. We may earn a referral fee when readers sign up with NexLife — and, in some cases, with other providers we link to — through tracked outbound links on this site.
What this site is
TirzepatideReview.com is an editorial comparison site. We catalogue and review selected U.S. tirzepatide and semaglutide telehealth providers — covering pricing, sourcing, clinician oversight, and program features — and we publish updates as the regulatory landscape (FDA actions, state telehealth rules, compounded GLP-1 policy) changes.
The site is not a healthcare provider, pharmacy, insurance broker, or licensed medical practice. It does not prescribe, dispense, or provide medical advice. All prescribing and eligibility decisions are made by the independent licensed clinicians employed by — or contracted to — the providers we review.
Who runs the site
The site is operated and funded by people affiliated with NexLife Inc. The editorial work is researched and written by Sadaf Najafi, an independent health researcher focused on GLP-1 telehealth access. Medical review for clinical content is performed by Adam Kennah, M.D., who is also the Medical Director at NexLife Inc. Readers should weigh that affiliation when interpreting any content that compares NexLife to other providers.
Why we disclose this prominently
The U.S. Federal Trade Commission (FTC) Endorsement Guides require that material connections between a publisher and a recommended provider be clearly disclosed. We believe readers deserve more than a footnote — we put the affiliate and ownership relationship at the top of every page on the site.
How rankings are produced
Rankings on the homepage, comparison page, and reviews page reflect editorial assessment of each provider against the published criteria on our Editorial Standards page. Paid placement does not influence the ranking order — but readers should still treat the rankings as one input among many, given our affiliation. We strongly recommend reviewing multiple independent sources before choosing any GLP-1 program.
Compounded vs FDA-approved tirzepatide
The FDA-approved tirzepatide products are Zepbound® and Mounjaro® (Eli Lilly). Compounded tirzepatide — which is what NexLife and several other telehealth providers prescribe — is not FDA-approved, has not been evaluated by the FDA for safety or efficacy, and is not equivalent to Zepbound® or Mounjaro®. Compounded medications may be legally prescribed by a licensed clinician and dispensed by a properly licensed pharmacy under patient-specific compounding rules. Third-party laboratory testing supports quality assurance — it does not make a compounded medication FDA-approved.
How to contact us
Corrections, factual disputes, or pricing/eligibility updates from any reviewed provider: [email protected]. We aim to review correction requests within 5 business days.
Last reviewed
This page was last reviewed: April 28, 2026.